Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTRON Study: Ferric Carboxymaltose for Iron Deficiency Anemia in Gastrointestinal Cancer Patients Receiving Chemotherapy
jRCTs051240288Active, not recruiting
- Sponsor
- Zeria Pharmaceutical Co., Ltd.
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ferric carboxymaltose in iron deficiency anemia (IDA), gastric adenocarcinoma and colorectal adenocarcinoma, sponsored by Zeria Pharmaceutical Co., Ltd. Primary endpoint: Rate of hemoglobin improvement at 8 weeks from initial administration. Started Mar 2025; status: active, not recruiting.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)gastric adenocarcinomacolorectal adenocarcinoma
Beyond the preview
Go deeper on jRCTs051240288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240288.